IL Biotechnology & Medical Research

Compugen Ltd (CGEN)

Track

Compugen Ltd experienced recent insider trading activity characterized by a planned sale of 1,875 shares valued at $4,687.50 by SVP Zurit Levine. This transaction occurred amidst a 15.7% decline in stock price over the last quarter, following the most recent earnings report released in August 2026.
Ticker: CGEN Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Levine Zurit SVP, Business Development Officer
Transaction date
Planned sale
Price
133.85
Quantity 39,440 +23.3%
Value US$752,107
Ophir Eran President and CEO Executive Director
Transaction date
Planned sale
Price
432.56
Quantity 58,748 -27.2%
Value US$132,679
Levine Zurit SVP, Business Development Officer
Transaction date
Planned sale
Price
436.54
Quantity 3,008 +41.5%
Value US$3,857,228
Ophir Eran Officer Officer
Transaction date
Proposed sale
Price
2.92
Quantity 5,000
Value US$14,600
Levine Zurit Officer Officer
Transaction date
Proposed sale
Price
2.92
Quantity 4,000
Value US$11,680
Ophir Eran President and CEO Executive Director
Transaction date
Planned sale
Price
2.90
Quantity 5,000 -30.5%
Value US$14,521
Levine Zurit SVP, Business Development Officer
Transaction date
Planned sale
Price
2.80
Quantity 2,000 -6.4%
Value US$5,600
Ophir Eran Officer Officer
Transaction date
Proposed sale
Price
2.76
Quantity 5,000
Value US$13,800
Levine Zurit Officer Officer
Transaction date
Proposed sale
Price
2.76
Quantity 2,000
Value US$5,520
Levine Zurit SVP, Business Development Officer
Transaction date
Planned sale
Price
2.56
Quantity 3,125 -9.6%
Value US$8,012
Levine Zurit Officer Officer
Transaction date
Proposed sale
Price
2.48
Quantity 2,000
Value US$4,960
Levine Zurit SVP, Business Development Officer
Transaction date
Planned sale
Price
2.42
Quantity 5,375 -15.5%
Value US$13,008
Levine Zurit SVP, Business Development Officer
Transaction date
Planned sale
Price
2.30
Quantity 2,500 -7.8%
Value US$5,750
Ophir Eran President and CEO Executive Director
Transaction date
Planned sale
Price
2.21
Quantity 5,625 -33.1%
Value US$12,413
Levine Zurit SVP, Business Development Officer
Transaction date
Planned sale
Price
2.20
Quantity 3,500 -10.6%
Value US$7,700
Ophir Eran Officer Officer
Transaction date
Proposed sale
Price
2.13
Quantity 5,625
Value US$11,981
Levine Zurit SVP, Business Development Officer
Transaction date
Planned sale
Price
2.04
Quantity 11,875 -28.8%
Value US$24,187
Levine Zurit Officer Officer
Transaction date
Proposed sale
Price
2.06
Quantity 24,375
Value US$50,212
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-13 2026-07-09 PlS Planned sale
Levine Zurit

SVP, Business Development

Officer
39,440 +23.3%
133.85
US$752,107 		39,440 +23.3% 133.85 US$752,107
2026-04-27 2026-04-24 PlS Planned sale
Ophir Eran

President and CEO

Executive Director
58,748 -27.2%
432.56
US$132,679 		58,748 -27.2% 432.56 US$132,679
2026-04-27 2026-04-24 PlS Planned sale
Levine Zurit

SVP, Business Development

Officer
3,008 +41.5%
436.54
US$3,857,228 		3,008 +41.5% 436.54 US$3,857,228
2026-04-27 2026-04-24 PrS Proposed sale
Ophir Eran

Officer

Officer
5,000
2.92
US$14,600 		5,000 2.92 US$14,600
2026-04-27 2026-04-24 PrS Proposed sale
Levine Zurit

Officer

Officer
4,000
2.92
US$11,680 		4,000 2.92 US$11,680
2026-04-15 2026-04-14 PlS Planned sale
Ophir Eran

President and CEO

Executive Director
5,000 -30.5%
2.90
US$14,521 		5,000 -30.5% 2.90 US$14,521
2026-04-15 2026-04-14 PlS Planned sale
Levine Zurit

SVP, Business Development

Officer
2,000 -6.4%
2.80
US$5,600 		2,000 -6.4% 2.80 US$5,600
2026-04-15 2026-04-14 PrS Proposed sale
Ophir Eran

Officer

Officer
5,000
2.76
US$13,800 		5,000 2.76 US$13,800
2026-04-15 2026-04-14 PrS Proposed sale
Levine Zurit

Officer

Officer
2,000
2.76
US$5,520 		2,000 2.76 US$5,520
2026-04-13 2026-04-10 PlS Planned sale
Levine Zurit

SVP, Business Development

Officer
3,125 -9.6%
2.56
US$8,012 		3,125 -9.6% 2.56 US$8,012
2026-04-13 2026-04-10 PrS Proposed sale
Levine Zurit

Officer

Officer
2,000
2.48
US$4,960 		2,000 2.48 US$4,960
2026-04-09 2026-04-08 PlS Planned sale
Levine Zurit

SVP, Business Development

Officer
5,375 -15.5%
2.42
US$13,008 		5,375 -15.5% 2.42 US$13,008
2026-04-09 2026-04-07 PlS Planned sale
Levine Zurit

SVP, Business Development

Officer
2,500 -7.8%
2.30
US$5,750 		2,500 -7.8% 2.30 US$5,750
2026-04-03 2026-04-01 PlS Planned sale
Ophir Eran

President and CEO

Executive Director
5,625 -33.1%
2.21
US$12,413 		5,625 -33.1% 2.21 US$12,413
2026-04-03 2026-04-01 PlS Planned sale
Levine Zurit

SVP, Business Development

Officer
3,500 -10.6%
2.20
US$7,700 		3,500 -10.6% 2.20 US$7,700
2026-04-02 2026-04-01 PrS Proposed sale
Ophir Eran

Officer

Officer
5,625
2.13
US$11,981 		5,625 2.13 US$11,981
2026-03-30 2026-03-26 PlS Planned sale
Levine Zurit

SVP, Business Development

Officer
11,875 -28.8%
2.04
US$24,187 		11,875 -28.8% 2.04 US$24,187
2026-03-26 2026-03-26 PrS Proposed sale
Levine Zurit

Officer

Officer
24,375
2.06
US$50,212 		24,375 2.06 US$50,212
Explore more

More insider trading research around Compugen Ltd

More insider trades in IL
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity